ESTRO 2021 Abstract Book

S544

ESTRO 2021

Debate: Hype or Hope? This house believes that the application of radiomics will significantly improve clinical outcome of radiotherapy by 2025

SP-0685 For the motion A. Traverso 1 1 Maastro Clinic, Radiotherapy, Maastricht, The Netherlands

Abstract Text Radiomics offers the possibility to re-think and revitalise imaging data in radiation oncology, beyond visual inspection. Since its first introduction in 2014, radiomic studies have shown the promising added value of imaging-derived biomarkers in supporting clinical decision making. However, the translational gap among the number of radiomic studies and corresponding decision support systems, as well as methodological pitfalls in radiomic methodology have created a distrust in this technology. I referred to this as the disillusionment phase, which is typical of every new technology, when first introduced to the clinical domain. This phase requires us to go beyond frustration and un-met expectations. It opens the space for newer developments, better research questions, and raised awareness. Also, the availability of deep learning neural networks can support tackling some of the major drawbacks of radiomic such as poor reliability, poor standardisation and harmonisation. This new radiomic renewal phase, if recognised as a unique opportunity, will push forward the applicability of radiomic in the clinic.

SP-0686 Against the motion A. Hope Canada

Abstract not available

Symposium: COVID-19: Lessons learned from a medical physics perspective

SP-0690 How did the first wave affect medical physics practice in Europe? ESTRO survey J. Bertholet 1 , M. Aznar 2 , C. Garibaldi 3 , D. Thwaites 4 , E. Gershvevitsh 5 , D. Thorwarth 6 , D. Verellen 7 , B. Heijmen 8 , C. Hurkmans 9 , L. Muren 10 , K. Røe Redalen 11 , F. Siebert 12 , M. Schwarz 13 , W. Van Elmpt 14 , D. Georg 15 , N. Jornet 16 , C. Clark 17 1 Bern University Hospital, Department of Radiation Oncology, Bern, Switzerland; 2 University of Manchester, Division of Cancer Sciences, Manchester, United Kingdom; 3 IEO European Institute of Oncology, Unit of Radiation Research, Milan, Italy; 4 University of Sydney, Institute of Medical Physics, Sydney , Australia; 5 North Estonia Medical Centre, Medical Physics, Tallinn, Estonia; 6 University Hospital Tübingen, Section for Biomedical Physics, Tübingen, Germany; 7 Antwerp University, Iridium Network, Antwerp , Belgium; 8 Erasmus MC Cancer Institute, Department of Radiotherapy, Rotterdam, The Netherlands; 9 Catharina Hospital, Department of Radiation Oncology, Eindhoven, The Netherlands; 10 Aarhus University Hospital, Danish Centre for Particle Therapy, Aarhus , Denmark; 11 Norwegian University of Science and Technology, Department of Physics, Trondheim, Norway; 12 University Hospital of Schleswig-Holstein, Clinic of Radiotherapy, Kiel, Germany; 13 Trento Hospital, Proton Therapy Department, Trento, Italy; 14 Maastricht University Medical Centre, Department of Radiation Oncology, Maastricht , The Netherlands; 15 Medical University of Vienna / AKH Wien, Division Medical Radiation Physics, Vienna , Austria; 16 Hospital de la Santa Creu i Sant Pau, Servei de Radiofísica i Radioprotecció, Barcelona, Spain; 17 University College London Hospital, Radiotherapy Physics, London, United Kingdom